{"entity":{"id":"nct03301805","kind":"trial","name":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial in pancreatic cancer, run by Rgene Corporation, not yet recruiting.","summary":"A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer is a phase 2, interventional study registered as NCT03301805 by Rgene Corporation, with a registry enrolment figure of 40 participants, started 2026-07-01 and due to reach its primary completion in 2027-04-30. Interventions recorded: BLEX 404. Conditions listed: Pancreatic Cancer. Primary outcome: Part I: Dose-limiting toxicity (DLT) observation; Part II: Overall response rate (PR + CR). Pancreatic eligibility wording from the registry: \"Patients with pathologically proved adenocarcinoma of pancreatic cancer and diagnosed with inoperable/metastatic disease (previous systemic chemotherapy, neoadjuvant or adjuvant gemcitabine are acceptable, unless exclusion criteria met)\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03301805","url":"https://clinicaltrials.gov/study/NCT03301805"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac","locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03301805","phase":"2","setting":"A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer","sponsor":"Rgene Corporation","participation":[{"nct":"NCT03301805","source":"https://clinicaltrials.gov/study/NCT03301805","fetchedAt":"2026-10-07T16:52:59.616Z","studySha256":"c7a73f27382bbdea8b4cd29ca00ac523ebe34249a5af3df616cd8f795c3dbf29","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-04-20","leadSponsor":"Rgene Corporation","collaboratorCount":1,"minimumAge":"20 Years","maximumAge":"80 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":0,"recruitingSiteCount":0}],"started":"2026-07-01","startedType":"estimated","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03301805/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}